NonSurgical Debridement

The Department of Health & Human Services' Administration for Strategic Preparedness and Response issued a Pre-Solicitation Notice regarding the procurement of enzymatic debridement products aimed at treating severe burn injuries for national preparedness against mass casualty incidents. The acquisition seeks products that enhance early intervention in burn care, potentially improving patient outcomes and optimizing resource allocation during emergencies. The initiative aims to establish a vendor-managed inventory (VMI) for enzymatic debridement products, ensuring a deployable cache that prevents expiration and waste while maintaining readiness for national emergencies. This procurement is supported by Project BioShield funding, with a contract expected around September 2025, and a performance period of up to 120 months. The notice serves to alert potential contractors of upcoming opportunities but does not request proposals at this time. Interested parties must be registered in the System for Award Management. Contacts are provided for Barriers regarding the project. This reflects the government's focus on creating effective and sustainable solutions in response to health threats posed by severe burn injuries.

The document is a Request for Proposals (RFP) issued by the Biomedical Advanced Research and Development Authority (BARDA) for the procurement and development of enzymatic debridement products for treating severe burn injuries. It aims to enhance national preparedness for mass casualty incidents by establishing a vendor-managed inventory (VMI) system that will ensure a ready supply of FDA-approved products. The RFP sets forth a detailed scope of work that includes initial procurement of products, maintenance of the preparedness inventory, emergency deployment capabilities, and the development of next-generation products with improved efficacy and stability. Key objectives include procuring a minimum of 2,750 units of enzymatic debridement products, ensuring compatibility with existing treatment protocols, and expanding product indications to include blast trauma. The contract involves a base period of ten years, with opportunities for additional options focusing on formulation development and clinical studies. Regular reporting, quality management, and adherence to FDA regulations are mandated, reflecting the government's commitment to robust medical countermeasure development. The ultimate goal is to improve patient outcomes and reduce healthcare resource burdens during emergency situations.

The amendment to the Request for Proposals (RFP) 75A50125R00007 issued by the Biomedical Advanced Research and Development Authority (BARDA) focuses on acquiring enzymatic debridement products for treating severe burn injuries. The amendment clarifies the proposal timeline, extending the deadline for questions to July 31, 2025, and proposals to August 27, 2025. The objective is to procure FDA-approved products that can remove necrotic tissue from burn wounds, specifically addressing the challenges of providing effective burn care, especially during mass casualty incidents. The proposal mandates that vendors establish a Vendor Managed Inventory (VMI) for rapid deployment of supplies, thereby reducing reliance on surgical interventions and facilitating better patient outcomes. The contract may span up to ten years and includes provisions for product procurement, maintenance, and potential next-generation product development. Key requirements include emergency deployment capabilities, operational management, collaboration with burn care centers, and adherence to FDA regulations. The overall aim is to enhance national healthcare preparedness through improved burn treatment technologies and systems aligned with federal healthcare standards.

This document, Amendment 0002 to Solicitation No. 75A50125R00007, addresses vendor questions regarding the RFP for "Enzymatic Debridement Products for Treatments of Deep and Full-Thickness Severe Burn Injuries." Key clarifications include: the Proposal Intent Response Form (Attachment 4) is not required; the Gantt/WBS/Milestones & Deliverables table should be part of the Statement of Work (SOW); the SOW should be submitted as part of the technical proposal and copied in the business proposal without a separate cover page; data/IP rights will incorporate FAR Clause 52.227-14; and the full text of HHSAR 352.204-75 is provided as an attachment. Additionally, the amendment clarifies requirements for proof of freedom to operate, separate costing for product unit cost and inventory management, anticipated frequency of on-site visits (at least annually) and emergency drills (at least three in the first, third, and fifth years), and defines "dose" according to the product's label indication. It also details delivery expectations for CLIN 003a, including Offeror responsibility for transportation, planning for farthest US destinations including territories, and the 24-hour window covering post-notification product shipment. The document notes that BARDA will work collaboratively on notification periods for additional volumes, and property disposition will follow agency policies. It encourages early initiation of CLIN008 for manufacturing development if feasible and strongly recommends pre-executed agreements and cost quotations from subcontractors. Finally, it states that proposals will be evaluated per Section M of the RFP, confirming the focus on FDA-approved enzymatic debridement products.

HHSAR Class Deviation 2025-01 outlines provisions for Supply Chain Risk Assessment (SCRA) for both proposals and active contracts within the Department of Health and Human Services (HHS). The deviation defines key terms such as "mission-critical acquisition," "supply chain risk," and "state-owned enterprise." It mandates that the Office of National Security (ONS) may conduct SCRAs, considering public and non-public information. Offerors and contractors must provide detailed information on products, vendors, and manufacturers. Furthermore, they are required to disclose foreign ownership, business affiliations, ties of company leadership to foreign countries, and any past violations of export controls or the Foreign Corrupt Practices Act, as well as debarments, bankruptcies, or litigation. Failure to provide this information can result in ineligibility for award or contract continuation. The deviation also stipulates that mitigation plans will be incorporated into contracts and that these provisions must be flowed down to subcontractors involved in mission-critical acquisitions.

This government Request for Proposals (RFP) from the Biomedical Advanced Research and Development Authority (BARDA) outlines an amendment (0001) to RFP #75A50125R00007 for “Enzymatic Debridement Products for Treatments of Deep and Full-Thickness Severe Burn Injuries.” The amendment extends the proposal submission deadline to August 27, 2025, at 2 p.m. ET and sets the question cutoff date for July 31, 2025, at 2 p.m. ET. The RFP aims to procure FDA-approved enzymatic debridement products and support the development of next-generation formulations for national burn care preparedness. Key objectives include establishing a Vendor-Managed Inventory (VMI) with a Preparedness Inventory (minimum 2750 units) for emergency deployment, ongoing VMI maintenance, and emergency deployment exercises. The contract, with a base period of up to ten years and six options, also covers advanced development, clinical studies, manufacturing development (preferably US-based), regulatory tasks for FDA approval, and potential expansion for use in blast trauma. Contractors must demonstrate infrastructure for inventory management and distribution, adhere to strict reporting requirements, and comply with various government regulations on subcontracts, security, and data rights.